-
Electronic (PDF)
-
Site License
-
Enterprisewide
Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, December 2011, Pages: 54
Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Kawasaki Disease Therapeutics market. The report identifies the key trends shaping and driving the global Kawasaki Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Kawasaki Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Kawasaki Disease Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Kawasaki Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Kawasaki Disease Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Kawasaki Disease Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Kawasaki Disease Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Kawasaki Disease Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Kawasaki Disease Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Kawasaki Disease Therapeutics market landscape? – Identify, understand and capitalize.
1
1
1.1 List of Tables
1.2 List of Figures
2 Kawasaki Disease - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.2 Mortality Rate
2.2.3 Quality of Life Parameters
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Clinical Findings
2.5.2 Laboratory Findings
2.5.3 Echocardiography (ECG)
2.5.4 Incomplete (Atypical) Kawasaki Disease
2.6 Treatment and Management Pattern
2.6.1 Initial Treatment
2.6.2 Long Term Management
2.6.3 Medicines and Tests
2.6.4 Medical Procedures and Surgery
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 Kawasaki DiseaseTherapeutics - Market Characterization
3.1 Overview
3.2 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - Global
3.3 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - Global
3.4 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - The US
3.5 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - The US
3.6 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - France
3.7 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - France
3.8 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - Germany
3.9 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - Germany
3.10 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - Italy
3.11 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - Italy
3.12 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - Spain
3.13 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - Spain
3.14 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - The UK
3.15 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - The UK
3.16 Kawasaki Disease Therapeutics Market Size (2005 - 2010) - Japan
3.17 Kawasaki Disease Therapeutics Market Forecast (2010 - 2018) - Japan
3.18 Drivers and Barriers for the Kawasaki Disease Therapeutics Market
3.18.1 Drivers for the Kawasaki Disease Therapeutics Market
3.18.2 Barriers for the Kawasaki Disease Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.19.1 Opportunity and Unmet Need in the Kawasaki Disease Therapeutics Market
3.20 Key Takeaway
4 Kawasaki DiseaseTherapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Major Therapies in the Kawasaki Disease Therapeutics Market
4.3.1 Overview
4.3.2 IVIG (Gammagard Liquid, Kiovig, Gamunex, Privigen, Octagam, Flebogamma)
4.4 Key Takeaway
5 Kawasaki Disease Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Kawasaki Disease Therapeutics Pipeline - Pipeline by Phase of Development
5.3.1 Kawasaki Disease Therapeutics - Phase III Clinical Pipeline
5.3.2 Kawasaki Disease Therapeutics - Phase II Pipeline
5.3.3 Kawasaki Disease Therapeutics - Phase I Pipeline
5.4 Kawasaki Disease Therapeutics Market - Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Key Takeaway
6 Kawasaki Disease Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/ Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Sponsors
6.5 Top Companies Participating in Therapeutic Clinical Trials
7 Kawasaki Disease Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Implications for Future Market Competition
8 Kawasaki Disease Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Baxter Biotherapeutics
8.2.2 Grifols Biologicals
8.2.3 CSL Behring
8.2.4 Talecris Biotherapeutics
8.2.5 Octapharma
9 Kawasaki Disease Therapeutics - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Epidemiology-based Forecasting
9.3.5 Primary Research
9.3.6 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography
1.1 List of Tables
Table 1: Phases of Kawasaki Disease
Table 2: Kawasaki Disease Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Table 3: Kawasaki Disease Therapeutics Market, Global, Forecast ($m ), 2010 - 2018
Table 4: Kawasaki Disease Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Table 5: Kawasaki Disease Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Table 6: Kawasaki Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 7: Kawasaki Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 8: Kawasaki Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 9: Kawasaki Disease Therapeutics Market, Germany, Forecast($m), 2010 - 2018
Table 10: Kawasaki Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 11: Kawasaki Disease Therapeutics Market, Italy, forecast ($m) 2010 - 2018
Table 12: Kawasaki Disease Therapeutics Market, Spain, Revenue($m), 2005 - 2010
Table 13: Kawasaki Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 14: Kawasaki Disease Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 15: Kawasaki Disease Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Table 16: Kawasaki Disease Therapeutics Market, Japan, Revenue ($m) 2005 - 2010
Table 17: Kawasaki Disease Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 18: Kawasaki Disease Therapeutics - Phase III Clinical Pipeline, 2011
Table 19: Kawasaki Disease Therapeutics - Phase II Clinical Pipeline, 2011
Table 20: Kawasaki Disease Therapeutics - Phase I Clinical Pipeline, 2011
Table 21: Kawasaki Disease Therapeutics Market, Clinical Trials by Country, 2011
Table 22: Kawasaki Disease Therapeutics Market, Clinical Trials by Phase, 2011
Table 23: Kawasaki Disease Therapeutics Market, Clinical Trials by Status, 2011
Table 24: Kawasaki Disease Therapeutics Market, Clinical Trials by Prominent Sponsors, 2011
Table 25: Kawasaki Disease Therapeutics Market, Clinical Trials by Top Companies, 2011
1.2 List of Figures
Figure 1: Referral Pathway for Kawasaki Disease
Figure 2: Kawasaki Disease Therapeutics Market, Global, Revenue ($m), 2005 - 2010
Figure 3: Kawasaki Disease Therapeutics Market, Global, Forecast ($m), 2010 - 2018
Figure 4: Kawasaki Disease Therapeutics Market, The US, Revenue ($m), 2005 - 2010
Figure 5: Kawasaki Disease Therapeutics Market, The US, Forecast ($m), 2010 - 2018
Figure 6: Kawasaki Disease Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 7: Kawasaki Disease Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 8: Kawasaki Disease Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 9: Kawasaki Disease Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 10: Kawasaki Disease Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 11: Kawasaki Disease Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 12: Kawasaki Disease Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 13: Kawasaki Disease Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 14: Kawasaki Disease Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 15: Kawasaki Disease Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 16: Kawasaki Disease Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 17: Kawasaki Disease Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 18: Opportunity and Unmet Need in the Kawasaki Disease Therapeutics Market, 2010
Figure 19: Strategic Competitor Assessment of the Major Marketed Products for Kawasaki Disease, 2011
Figure 20: Kawasaki Disease - Pipeline by Phase of Development, 2011
Figure 21: Kawasaki Disease Therapeutics Market - Pipeline by Mechanism Of Action, 2011
Figure 22: Technology Trends Analytic Framework of the Kawasaki Disease Therapeutics Pipeline- Description, 2011
Figure 23: Technology Trends Analytic Framework of the Kawasaki Disease Therapeutics Pipeline- Description, 2011
Figure 24: Kawasaki Disease Therapeutics Market, Clinical Trials by Country, 2011
Figure 25: Kawasaki Disease Therapeutics Market - Clinical Pipeline by Phase, 2011
Figure 26: Kawasaki Disease Therapeutics Market- Clinical Trials by Status
Figure 27: Kawasaki Disease Therapeutics Market - Clinical Trials by Overall Sponsors (%), 2011
Figure 28: Kawasaki Disease Therapeutics Market - Clinical Trials by Prominent Sponsors (%), 2011
Figure 29: Kawasaki Disease Therapeutics Market - Number of Clinical Trials by Top Companies, 2011
Figure 30: Kawasaki Disease Therapeutics Market, Drivers and Barriers, 2011
Figure 31: Implications for Future Market Competition in the Kawasaki Disease Therapeutics Market, 2011
Figure 32: GlobalData Market Forecasting Model
GlobalData, the industry analysis specialist, has released its new report, “Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Kawasaki disease market, which identifies the key trends shaping and driving the market, provides insights on the prevalent competitive landscape, and highlights the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Kawasaki disease sector. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.
The Kawasaki Disease Therapeutics Market is Forecast to Show Stagnant Growth until 2018
GlobalData estimates that the global Kawasaki disease therapeutics market was valued at $36m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2.4% to reach $43m in 2018. This growth is primarily attributed to the increase in incidence of Kawasaki disease and awareness of the disease among patients and physicians.
Kawasaki Disease Therapeutics Market, Global, Revenue ($m), 2005 - 2018
Source: GlobalData, Centre for Disease Control and Prevention (CDC); Kawasaki disease in England: ethnicity, deprivation, and respiratory pathogens, 2009; Rising incidence of Kawasaki disease in England: analysis of hospital admission data, 2002, British Medical Journal (BMJ).
Current Treatment Options are Moderately Successful in Meeting the Market Demand
GlobalData’s research indicates that the only approved drug, Intravenous Immunoglobulins (IVIGs) has been successful in treating the symptoms of the disease. The mechanism of action of IVIGs in Kawasaki disease is unknown but the therapy has been effective in providing symptomatic relief. The Food and Drug Administration (FDA) and European Medicine Agency (EMA) have approved IVIGs including Gamunex, Gammagard (Gammagard Liquid + rHuPH20), Octagem, Flebogamma and Privigen. Aspirin is used as an off-label drug in combination with IVIGs for the treatment of the symptoms of Kawasaki disease.
The Kawasaki Disease Therapeutics Market has High Unmet Need
The global Kawasaki disease therapeutics market has a high degree of unmet need due to the symptom-oriented nature of available treatments. There is currently no cure for Kawasaki disease. IVIG is a biologic and the therapy is found to have a high cost, although the safety and efficacy profiles of the treatment are strong.
Lack of Pipeline Products Likely to Result in a Stagnant Market for Kawasaki Disease
GlobalData’s pipeline analysis reveals that there are five molecules in the various stages of clinical development, none of which are first-in-class molecules. This indicates that pharmaceutical companies are not focused on Research and Development (R&D) of new therapies for Kawasaki disease. Current treatments are effective but provide symptomatic relief only. The Kawasaki disease market offers significant opportunity for the entrants who have better safety and efficacy profiles and are inexpensive. New entrants would need to focus on providing a cure for the disease in order to capture a large share of the Kawasaki disease therapeutics market.
Baxter Biotherapeutics
Grifols Biologicals
CSL Behring
Talecris Biotherapeutics
Octapharma
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
